Skip to main content
. 2019 Jul 24;8(8):1088. doi: 10.3390/jcm8081088

Figure 5.

Figure 5

A 47-year-old patient with glioblastoma showed a strong uptake of FMISO before the bevacizumab treatment (upper row), but the FMISO uptake disappeared after the treatment (lower row). This patient was considered a ‘MRI-FMISO double responder’.